Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and
exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases.
The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes
Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B
cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate,
DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus
vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For
more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical
product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated
myasthenia gravis. For more information, visit www.cabalettabio.com.
exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases.
The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes
Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B
cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate,
DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus
vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For
more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical
product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated
myasthenia gravis. For more information, visit www.cabalettabio.com.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Total raised: $125M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| 28.05.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.10.2019 | IPO | $75M | - |
| 10.01.2019 | Series B | $50M | - |
Mentions in press and media 16
| Date | Title | Description |
| 27.07.2024 | Promising Advances in ALS and Retinal Degeneration Treatments: A New Hope for Patients | In the realm of medical research, hope often flickers like a candle in the dark. Recent breakthroughs in treatments for Amyotrophic Lateral Sclerosis (ALS) and retinal degenerations illuminate this path, offering new possibilities for patie... |
| 25.07.2024 | IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE) | SHANGHAI, NANJING, China and SAN JOSE, Calif. , July 25, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell the... |
| 08.12.2022 | Cabaletta Bio Announces $35 Million Offering | /EIN News/ -- PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell the... |
| 08.12.2022 | Cabaletta Bio Announces $35 Million Offering | - |
| 11.10.2022 | IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder | PHILADELPHIA and SAN JOSE, Calif. and NANJING and SHANGHAI, China, Oct. 11, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing i... |
| 30.03.2022 | A team at Penn says it has slashed CAR-T cell therapy manufacturing timeframe to just 24 hours | The future of CAR-T cell therapy research has come a long way over the years, but scientists have still been plagued by one problem: how to cut down on the timeframe, which typically takes between 9 and 14 days. Except now. Researchers at P... |
| 28.10.2019 | University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO | Clinical-stage biotech company Cabaletta Bio Inc. announced that it had raised $74.8 million in an initial public offering Friday. The University City-based company sold 6.8 million shares of common stock at $11 per share, according to a co... |
| 09.01.2019 | Cabaletta Bio Closes $50M Series B Financing | Cabaletta Bio Inc., a Radnor, PA-based biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing. Backers included new investors Deerfield Ma... |
| 08.01.2019 | Term Sheet — Tuesday, January 8 | THE STUDENT DEBT BUBBLE Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Outstanding student debt hit $1.5 trillion for the first time ever in 2018, and it doesn’t seem to be getting be... |
| 08.01.2019 | Daily funding roundup - January 8th, 2019 | LendingFront raised $4M; Headset raised $12.1M; Managed by Q raised $25M; Humatics raised $28M Carson Living: Carson is a real estate tech startup that provides services to unstaffed residential buildings. Carson has raised $3 million in se... |
Show more